ClinicalTrials.gg
CompletedNCT06974825Updated May 16, 2025

A Study of BGM0504 in Chinese Patients With Type 2 Diabetes

A Phase 2 interventional study of BGM0504 Administered SC and BGM0504 Administered SC in Type 2 Diabetes, sponsored by BrightGene Bio-Medical Technology Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-05-16.

Sponsored by BrightGene Bio-Medical Technology Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2024, 2 years 3 months ago, and no results have been posted to the registry.
  • Registered 1 year 8 months after the study started (first participant enrolled Aug 2023, registered May 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
67
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 909 studies in Diabetes Mellitus, Type 2 with a site in China — 205 open to participants now, 228 under way, 46 of them phase 3. Diabetes Mellitus, Type 2 · China.

Enrollment
553rd of 767
67 · median 199
Started
2023
with 61 others
Phase 2
61 of 909
14 open now
Registered
751st of 909
by date

Among the 909 studies in Diabetes Mellitus, Type 2 with a site in China, this one is the 553rd largest by enrollment of the 767 interventional ones that give a count, is one of 62 that started in 2023, is one of 61 in phase 2, and was the 751st registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

205 of the 909 studies in Diabetes Mellitus, Type 2 with a site in China are open now. Recruiting first, the newest first:

200 more — sign in →

All 205 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 909 studies in Diabetes Mellitus, Type 2 with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of BGM0504 in Chinese patients with Type 2 Diabetes.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have been diagnosed with type 2 diabetes mellitus (T2DM);
  • Glycosylated () at screening/baseline: 7.0% ≤ HbA1c ≤ 10%;
  • (BMI): 19.5 kg/m2 ≤ BMI ≤ 35.0 kg/m2;
  • Fasting blood glucose (FPG) at screening/baseline: FPG ≤ 13.3 mmoL/L

Exclusion criteria

Exclusion Criteria:

  • Diagnosed with non-type 2 diabetes mellitus;
  • Grade 3 hypoglycemia within 6 months prior to screening;
  • Concomitant thyroid dysfunction that cannot be controlled at a stable drug dose at screening, or abnormalities in thyroid function test results at screening that require initiation of therapy;
  • Subjects with uncontrolled hypertension after treatment (systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg at screening) or untreated blood pressure meeting the above criteria at screening;
  • Patients with a previous history or clinical evidence of acute or chronic pancreatitis;
  • Malignant tumor confirmed within 5 years prior to screening (except cured carcinoma in situ) or potential malignant tumor assessed at screening;
  • Patients with severe mental illness or language disorder at screening, unwilling or unable to fully understand and cooperate;
  • Female subjects during pregnancy or lactation.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
67 participants (actual)

Study arms

  • Experimental
    5 mg BGM0504

    Drug: BGM0504 Administered SC

  • Experimental
    10 mg BGM0504

    Drug: BGM0504 Administered SC

  • Experimental
    15 mg BGM0504

    Drug: BGM0504 Administered SC

  • Experimental
    1 mg Semaglutide

    Drug: Semaglutide Administered SC

  • Experimental
    Placebo

    Drug: Placebo Administered SC

Interventions

  • 5 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week.

  • Experimental: 10 mg BGM0504 10 mg BGM0504 administered SC once a week.

  • Experimental: 15 mg BGM0504 15 mg BGM0504 administered SC once a week.

  • DrugSemaglutide Administered SC

    Active Comparator: 1 mg Semaglutide 1 mg semaglutide administered SC once a week

  • DrugPlacebo Administered SC

    Placebo Comparator: Placebo Placebo administered SC once a week.

This study also gives Semaglutide. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin A1c (HbA1c)

    Change from baseline in HbA1c after 12 weeks of treatment.

    Time frame: Week 0 to Week 12

Secondary outcomes

  1. Change From Baseline in Body Weight

    Change from baseline in body weight after 12 weeks of treatment.

    Time frame: Week 0 to Week 12

  2. Percentage of Participants With HbA1c Target Value of <7%

    Percentage of Participants With HbA1c Target Value of \<7% after 12 weeks of treatment.

    Time frame: Week 0 to Week 12

  3. Percentage of Participants With HbA1c Target Value of <6.5%

    Percentage of Participants With HbA1c Target Value of \<5.7% after 12 weeks of treatment.

    Time frame: Week 0 to Week 12

  4. Change From Baseline in Fasting Serum Glucose

    Change from baseline in FPG after 12 weeks of treatment.

    Time frame: Week 0 to Week 12

07

Study locations

1 site
  • The Third Xiangya Hospital of Central South University
    Changsha, Hunan, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in Aug 2024, 11 months.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 11 months is below that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2025
First posted
May 16, 2025
StartActual
Aug 30, 2023
Primary completionActual
Aug 13, 2024
CompletionActual
Aug 13, 2024
Last update
May 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06974825
Responsible party
Sponsor
First posted
May 16, 2025
Start date
Aug 30, 2023
Primary completion
Aug 13, 2024
Completion
Aug 13, 2024
Last update
May 16, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BGM0504

Start the discussion